Skip to content

Author

M. Suárez-Calvet

We have 6 of 351 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Cognitive vergence and pupillary responses as functional oculomotor signatures to differentiate AT(N) biological profiles in older adults with mild cognitive impairment

The locus coeruleus (LC), the earliest site of tau accumulation in Alzheimer’s disease, directly influences pupillary and vergence oculomotor systems. Whether task-evoked oculomotor dynamics can non-invasively differentiate AT(N) profiles, A+T+ (biological Alzheimer’s disease) and A−T+ (suspected non-Alzheimer’s tauopa...

Ricardo Martínez-Flores, Isabel Martín-Sobrino, Neus Falgàs et al. · 0 citations
Review Aug 2026

Caregivers and technology: Digital content assessment on Alzheimer’s disease

This study examined caregivers' preferences for digital content to support the care of individuals with dementia, particularly those with Alzheimer's disease (AD). An online survey was conducted with 147 caregivers affiliated with the Pasqual Maragall Foundation, assessing the perceived usefulness of content across...

D. Piromalli, Gloria Mas Vall-llosera, M. Ivirico et al. · 0 citations
Open access Aug 2026

Big tau and brain-derived tau reveal peripheral and central nervous system involvement in neuropathies

INTRODUCTION: Biomarkers for monitoring disease activity and treatment response in peripheral neuropathies remain limited. Big tau, a high-molecular-weight isoform of tau, is predominantly expressed in the peripheral nervous system (PNS). We investigated serum levels of big tau, brain-derived tau (BD-tau), and neurofil...

L. Martín-Aguilar, F. González-Ortiz, H. Zetterberg et al. · 0 citations
Review Open access Sep 2026

Sociodemographic and clinical characteristics of participants in blood p-tau217 studies for Alzheimer's disease: A systematic review.

Overall, current evidence on p-tau217 is derived mainly from selected populations and may not fully reflect real-world clinical diversity, so future studies should prioritize more representative cohorts and standardized reporting of key variables will be essential to strengthen its adoption in clinical practice.

M. T. Blasi, Simona Buscarnera, M. Salzillo et al. · 0 citations
Open access Aug 2026

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer’s disease

In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury.

W. Pelkmans, R. Cacciaglia, Michalis Kassinopoulos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.